Last reviewed · How we verify

pioglitazone + simvastatin — Competitive Intelligence Brief

pioglitazone + simvastatin (pioglitazone + simvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione + HMG-CoA reductase inhibitor combination. Area: Endocrinology / Cardiovascular.

marketed Thiazolidinedione + HMG-CoA reductase inhibitor combination PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin) Endocrinology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

pioglitazone + simvastatin (pioglitazone + simvastatin) — University of Leipzig. This combination reduces blood glucose through insulin sensitization (pioglitazone) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
pioglitazone + simvastatin TARGET pioglitazone + simvastatin University of Leipzig marketed Thiazolidinedione + HMG-CoA reductase inhibitor combination PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione + HMG-CoA reductase inhibitor combination class)

  1. University of Leipzig · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pioglitazone + simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/pioglitazone-simvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: